{"name":"Shanghai Henlius Biotech","slug":"shanghai-henlius-biotech","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":22,"colorKey":"oncology","drugs":[{"name":"EU-sourced Keytruda®","genericName":"EU-sourced Keytruda®","slug":"eu-sourced-keytruda","indication":"Metastatic melanoma","status":"phase_3"},{"name":"EU-Perjeta®","genericName":"EU-Perjeta®","slug":"eu-perjeta","indication":"HER2-positive metastatic breast cancer","status":"phase_3"},{"name":"EU-sourced YERVOY®","genericName":"EU-sourced YERVOY®","slug":"eu-sourced-yervoy","indication":"Metastatic melanoma","status":"phase_3"},{"name":"HLX04, a bevacizumab biosimilar","genericName":"HLX04, a bevacizumab biosimilar","slug":"hlx04-a-bevacizumab-biosimilar","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"HLX10","genericName":"HLX10","slug":"hlx10","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX10, an engineered anti-PD-1 antibody","genericName":"HLX10, an engineered anti-PD-1 antibody","slug":"hlx10-an-engineered-anti-pd-1-antibody","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX11","genericName":"HLX11","slug":"hlx11","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX22","genericName":"HLX22","slug":"hlx22","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"US-sourced YERVOY®","genericName":"US-sourced YERVOY®","slug":"us-sourced-yervoy","indication":"Metastatic melanoma","status":"phase_3"},{"name":"carboplatin and nab paclitaxel","genericName":"carboplatin and nab paclitaxel","slug":"carboplatin-and-nab-paclitaxel","indication":"Non-small cell lung cancer (phase 3 development)","status":"phase_3"},{"name":"Cetuximab Injection [Erbitux]","genericName":"Cetuximab Injection [Erbitux]","slug":"cetuximab-injection-erbitux","indication":"Metastatic colorectal cancer","status":"phase_2"},{"name":"Darzalex","genericName":"Darzalex","slug":"darzalex","indication":"Multiple myeloma","status":"marketed"},{"name":"HLX02","genericName":"HLX02","slug":"hlx02","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX03","genericName":"HLX03","slug":"hlx03","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX04","genericName":"HLX04","slug":"hlx04","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"HLX04-O","genericName":"HLX04-O","slug":"hlx04-o","indication":"Metastatic colorectal cancer","status":"phase_3"},{"name":"HLX13","genericName":"HLX13","slug":"hlx13","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX14","genericName":"HLX14","slug":"hlx14","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX15-IV","genericName":"HLX15-IV","slug":"hlx15-iv","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX17","genericName":"HLX17","slug":"hlx17","indication":"Non-small cell lung cancer","status":"phase_3"},{"name":"HLX208","genericName":"HLX208","slug":"hlx208","indication":"Non-small cell lung cancer, PD-L1 positive","status":"phase_2"},{"name":"carboplatin/cisplatin-etoposide","genericName":"carboplatin/cisplatin-etoposide","slug":"carboplatin-cisplatin-etoposide","indication":"Small cell lung cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"immunology","drugs":[{"name":"HLX301","genericName":"HLX301","slug":"hlx301","indication":"Other","status":"phase_1"},{"name":"HLX48","genericName":"HLX48","slug":"hlx48","indication":"Other","status":"phase_1"},{"name":"POHERDY","genericName":"PERTUZUMAB-DPZB","slug":"pertuzumab-dpzb","indication":"Other","status":"marketed"},{"name":"HLX26","genericName":"HLX26","slug":"hlx26","indication":"Other","status":"phase_2"},{"name":"HLX43 Dose 1;","genericName":"HLX43 Dose 1;","slug":"hlx43-dose-1","indication":"Other","status":"phase_2"},{"name":"US-sourced Keytruda®","genericName":"US-sourced Keytruda®","slug":"us-sourced-keytruda","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"EU-sourced Keytruda®","genericName":"EU-sourced Keytruda®","slug":"eu-sourced-keytruda","phase":"phase_3","mechanism":"Keytruda (pembrolizumab) is a monoclonal antibody that blocks the PD-1 checkpoint protein on immune cells, allowing them to recognize and attack cancer cells.","indications":["Metastatic melanoma","Non-small cell lung cancer (NSCLC)","Head and neck squamous cell carcinoma","Hodgkin lymphoma","Urothelial carcinoma"],"catalyst":""},{"name":"HLX301","genericName":"HLX301","slug":"hlx301","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EU-Perjeta®","genericName":"EU-Perjeta®","slug":"eu-perjeta","phase":"phase_3","mechanism":"EU-Perjeta is a monoclonal antibody that binds to HER2 and blocks its dimerization with other HER family receptors, inhibiting tumor cell growth signaling.","indications":["HER2-positive metastatic breast cancer","HER2-positive early breast cancer (neoadjuvant and adjuvant settings)"],"catalyst":""},{"name":"EU-sourced YERVOY®","genericName":"EU-sourced YERVOY®","slug":"eu-sourced-yervoy","phase":"phase_3","mechanism":"YERVOY (ipilimumab) blocks CTLA-4 on T cells, removing an inhibitory signal and enhancing anti-tumor immune responses.","indications":["Metastatic melanoma","Advanced renal cell carcinoma","Metastatic colorectal cancer (microsatellite instability-high)","Hepatocellular carcinoma"],"catalyst":""},{"name":"HLX04, a bevacizumab biosimilar","genericName":"HLX04, a bevacizumab biosimilar","slug":"hlx04-a-bevacizumab-biosimilar","phase":"phase_3","mechanism":"HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer","Ovarian cancer"],"catalyst":""},{"name":"HLX10","genericName":"HLX10","slug":"hlx10","phase":"phase_3","mechanism":"HLX10 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX10, an engineered anti-PD-1 antibody","genericName":"HLX10, an engineered anti-PD-1 antibody","slug":"hlx10-an-engineered-anti-pd-1-antibody","phase":"phase_3","mechanism":"HLX10 is an engineered anti-PD-1 monoclonal antibody that blocks the PD-1 checkpoint on T cells, allowing them to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation in Phase 3)"],"catalyst":""},{"name":"HLX11","genericName":"HLX11","slug":"hlx11","phase":"phase_3","mechanism":"HLX11 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX22","genericName":"HLX22","slug":"hlx22","phase":"phase_3","mechanism":"HLX22 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX48","genericName":"HLX48","slug":"hlx48","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"POHERDY","genericName":"PERTUZUMAB-DPZB","slug":"pertuzumab-dpzb","phase":"marketed","mechanism":"","indications":[],"catalyst":""},{"name":"US-sourced YERVOY®","genericName":"US-sourced YERVOY®","slug":"us-sourced-yervoy","phase":"phase_3","mechanism":"YERVOY is a monoclonal antibody that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","indications":["Metastatic melanoma","Adenocarcinoma of the microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors","Colorectal cancer","Renal cell carcinoma","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"carboplatin and nab paclitaxel","genericName":"carboplatin and nab paclitaxel","slug":"carboplatin-and-nab-paclitaxel","phase":"phase_3","mechanism":"This combination uses carboplatin to cross-link DNA and nab-paclitaxel to stabilize microtubules, together inducing cancer cell death through complementary cytotoxic mechanisms.","indications":["Non-small cell lung cancer (phase 3 development)","Ovarian cancer (potential indication)"],"catalyst":""},{"name":"Cetuximab Injection [Erbitux]","genericName":"Cetuximab Injection [Erbitux]","slug":"cetuximab-injection-erbitux","phase":"phase_2","mechanism":"Cetuximab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), preventing cancer cell growth and proliferation.","indications":["Metastatic colorectal cancer","Head and neck squamous cell carcinoma"],"catalyst":""},{"name":"Darzalex","genericName":"Darzalex","slug":"darzalex","phase":"marketed","mechanism":"Lymphocyte differentiation antigen CD38","indications":["Multiple myeloma","Systemic AL amyloidosis"],"catalyst":""},{"name":"HLX02","genericName":"HLX02","slug":"hlx02","phase":"phase_3","mechanism":"HLX02 is a monoclonal antibody that binds to and blocks the PD-1 checkpoint receptor on immune cells, allowing them to recognize and attack cancer cells.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX03","genericName":"HLX03","slug":"hlx03","phase":"phase_3","mechanism":"HLX03 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX04","genericName":"HLX04","slug":"hlx04","phase":"phase_3","mechanism":"HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"HLX04-O","genericName":"HLX04-O","slug":"hlx04-o","phase":"phase_3","mechanism":"HLX04-O is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.","indications":["Metastatic colorectal cancer","Non-small cell lung cancer","Metastatic breast cancer"],"catalyst":""},{"name":"HLX13","genericName":"HLX13","slug":"hlx13","phase":"phase_3","mechanism":"HLX13 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Other solid tumors (in development)"],"catalyst":""},{"name":"HLX14","genericName":"HLX14","slug":"hlx14","phase":"phase_3","mechanism":"HLX14 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and B7.1 to enhance anti-tumor immune responses.","indications":["Non-small cell lung cancer","Gastric cancer","Esophageal cancer"],"catalyst":""},{"name":"HLX15-IV","genericName":"HLX15-IV","slug":"hlx15-iv","phase":"phase_3","mechanism":"HLX15-IV is a humanized monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX17","genericName":"HLX17","slug":"hlx17","phase":"phase_3","mechanism":"HLX17 is a monoclonal antibody that binds to and inhibits PD-L1, blocking its interaction with PD-1 and restoring anti-tumor immune responses.","indications":["Non-small cell lung cancer","Other solid tumors (under investigation)"],"catalyst":""},{"name":"HLX208","genericName":"HLX208","slug":"hlx208","phase":"phase_2","mechanism":"HLX208 is a monoclonal antibody targeting PD-1.","indications":["Non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"HLX26","genericName":"HLX26","slug":"hlx26","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"HLX43 Dose 1;","genericName":"HLX43 Dose 1;","slug":"hlx43-dose-1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"US-sourced Keytruda®","genericName":"US-sourced Keytruda®","slug":"us-sourced-keytruda","phase":"phase_3","mechanism":"Keytruda is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.","indications":[],"catalyst":""},{"name":"carboplatin/cisplatin-etoposide","genericName":"carboplatin/cisplatin-etoposide","slug":"carboplatin-cisplatin-etoposide","phase":"phase_3","mechanism":"Carboplatin and cisplatin-etoposide work by interfering with DNA replication in cancer cells, ultimately leading to cell death.","indications":["Small cell lung cancer","Non-small cell lung cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxNTjMxVFhfOU56V1pzOFFxWWd2eWIzMTNTS1BUd1A3NFJjVGpqR0dFX2JEdTJpX1BwcnNicXdlLWVPM1BRbmVRcU5TSzN5Uy1QNDRqbUw0QXRGXzIyMU9qSmFjNU5CNzB4ZzNhRHdFb3RkS2RmRDlpanM3VzFsUDRQeW52NVJwWlVQcWhELXV1OV9hdjNsX1VqbVEydmNwVjJ5N0w4MTNpNS1pUlZvNVpEU0V5blZsbkZraFFpWVpYQURXZHFXNnZ4dGU3QVZuS2dqRWc?oc=5","date":"2026-02-06","type":"deal","source":"reuters.com","summary":"Eisai strikes Japan licensing deal with Shanghai Henlius Biotech - reuters.com","headline":"Eisai strikes Japan licensing deal with Shanghai Henlius Biotech","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-06","type":"deal","source":"South China Morning Post","summary":"Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal - South China Morning Post","headline":"Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOS2JEYWtNUGFwY0YxTVZPa19RMVR4ZlFCQ1VYbnNXMmZLMmdEUnI2dVgzUElLeloyV0xFTlpqR01sWGhMTVE2VTBoN3cxa2ZXTXBXbzh5WWxtMDV2TVVxTzV1M2lnLUg2Y19YUzVDaDJCVUxOcTdSNXVKdzktZHBkQURPeUVEZmJFR2VCM1huZHg2c0V2bzF0V3BFZ2hRcnNqNFJiYmp0NUxjeGk3ejJpWFNPNDJoVnBEWlpzTDlUU19qZw?oc=5","date":"2025-11-21","type":"pipeline","source":"Fierce Pharma","summary":"Fierce Pharma Asia—US-China supply chain ties; Bayer biotech incubator; Henlius biosim nod - Fierce Pharma","headline":"Fierce Pharma Asia—US-China supply chain ties; Bayer biotech incubator; Henlius biosim nod","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPbWM1OVBVeUMxdzYxNlo4c1Z4eVRxTkNSdmxCaXllUG85RDFibXBzOVVBQ2tidTNvSkxHeDF4Si12Q1d2d0dMY09qZk8zUEpmVHhLRjl0b0xhZTRhQnZBQkVtREx5ckU2X2h5dmIyVlpHWE9iTHE3VjJyaTVYTGl4RFJYVGZrOWNDbkJtLUFxOHlwNDVlS3hBYmViWkp2VGUydFFsNkVHaTVnUmg5?oc=5","date":"2025-11-14","type":"regulatory","source":"Fierce Pharma","summary":"Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod - Fierce Pharma","headline":"Organon and Henlius' Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-16","type":"pipeline","source":"South China Morning Post","summary":"Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug - South China Morning Post","headline":"Fosun’s Henlius in talks with Johnson & Johnson, Roche on cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxOeW5fdk0yT29ZalM5cTVmSUc3bHdsTFRpRFBwMS1jWFpFZ2FWNWhyYldtSGZGZkJsczBObzRhVEJkTG8xbmtwT2IyaDQzQWtEbmMzY0IyN1QyVklYNGloT1BLcS1xUXRiejVSUGlJeTlsRHp5X3JYSkRFU0Z2QTRBRVFHaEVyS1pZR0dKNWNGV3B6c0h6cFJIYnZRRzdPY2JFSzIyMzN2S0g2eVdlT19MTjRSdw?oc=5","date":"2025-09-15","type":"pipeline","source":"Bloomberg.com","summary":"Fosun’s Henlius Is Said in Talks With J&J, Roche on Cancer Drug - Bloomberg.com","headline":"Fosun’s Henlius Is Said in Talks With J&J, Roche on Cancer Drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQN0JmN0VUbmdSY1QtcDdJS2Q2WXV3WjllTktmV0pPcDRGemhwQUxUNEJoa0gtQXo2VWtZaHh4LVhwaHoyQzhCRndYeW80RVBYRGw3ZWp6X05nRXJQclYtVW8zcWRMd2RIcnlhQldTSnNLMWFiZjdLQjVxVGFLSEFBTERmMThZV0JtaWZvWkZ5TlZqYTFBTXgtdjVXV01ZZC0zZFdmWkdBNUEzSkwwU1gyeQ?oc=5","date":"2025-09-05","type":"deal","source":"Fierce Pharma","summary":"Fierce Pharma Asia—Novartis' $5B Argo deal; Eisai's subcutaneous Leqembi nod; HKEX chastises Henlius - Fierce Pharma","headline":"Fierce Pharma Asia—Novartis' $5B Argo deal; Eisai's subcutaneous Leqembi nod; HKEX chastises Henlius","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQUDBSWHZRTmg4cHFQNHpHQ3N1Qkg1a2EtVmRqMVV6d2g1ekVxX2EydF9QQndMS3V2cEc2QVBpMWtBNEtRNE9BNlh5cTFuc0lVaWlLd0ZYSEZhb3I2NXJ4VS1CYS1WeGlsbGpWdkJ6SGZBNkotbHBtQm1yNXZRR1d1N0hLV3Z1ZVhRc2E5YWxfMFdNeWp5U203UTh0ejJsVkdZOHVVZ3hQTl9vaWs4c3drZVhOMTlJQ2trNWhWRDktcw?oc=5","date":"2025-07-01","type":"trial","source":"Fierce Biotech","summary":"Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker - Fierce Biotech","headline":"Fosun's Henlius pens $202M pact for regional rights to HanchorBio's phase 2 CD47 blocker","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxPaGdwYXc1SWhTcFluMkNYb2wwUzhjNzVQVGtlTF81dHR4eUVCTktIMWZQSXQtNFo1cVdwVGFQcWVtQ2pQVkFwU1JlUWlmRU1vcXp0b3JmaHZxMWRBM29fRDkzRXlLQmg5UU5YQURFbmpBbC1mQmtQb2l1YWE3OWFJdUVPRGhFS09LVURKR09yOGJFWFg1Unpyd0JZRzZNcTIxeXhaSDRGZWhWWDdpSHFaWmNEd0JVeXNZTXVhMFp5WQ?oc=5","date":"2025-04-22","type":"pipeline","source":"Yicai Global","summary":"China’s Fosun Pharma to Hike Stake in Henlius After Failed Privatization Bid; Shares Gain - Yicai Global","headline":"China’s Fosun Pharma to Hike Stake in Henlius After Failed Privatization Bid; Shares Gain","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFA1Tl9qTkF6LWY2dkJUOGNwUnJkS3dhNHZ4ZWhBaEpNM0xkZUh4T2RKT3BpNEhMYmtaOTgtV0g1eUl3NG8yZS11ekpKNWpIOFRfS2xhYVkzUWZZOHdKWFlwUg?oc=5","date":"2024-01-11","type":"deal","source":"复宏汉霖","summary":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene-Media - 复宏汉霖","headline":"Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasof","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNWWJUOFZfRnhjUHl5ZHhmWTNWdzE2SkJieTY2QXZ1MzNXVnV0UEQ4NE53OF80NGlxazlvbnpQTmgzY3VQb1BkRjhuSXJBNFhITFdqSzZkV3hwdVdfa1VBNU9SNlctaVYtZGpqcTA1dnNhejRmbGtoYUNaLWs1ZFUtd2N5cjZlRGVoRWp2S0lndmRpWF9lRDFrdnc3bmJ4YzlYelJheURvTHpVZw?oc=5","date":"2022-05-09","type":"deal","source":"Generics and Biosimilars Initiative","summary":"Henlius makes deal with Getz Pharma for adalimumab copy biological - Generics and Biosimilars Initiative","headline":"Henlius makes deal with Getz Pharma for adalimumab copy biological","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE5YdXhIdlZsSWV2NnhGbEpRT3d1SVZ5WXVHV0hWclJKb1NlcHZBUWt6WDNULXB2MFlncGxSb2J4UEY0SFFoNkdoNkdLd3RnVjRfXzBYM21vOHZaaldjbW1Z?oc=5","date":"2020-09-01","type":"pipeline","source":"nature.com","summary":"Henlius: using a fully integrated platform to advance high-quality, affordable biologics - nature.com","headline":"Henlius: using a fully integrated platform to advance high-quality, affordable biologics","sentiment":"neutral"}],"patents":[],"drugCount":28,"phaseCounts":{"phase_3":20,"phase_1":2,"marketed":2,"phase_2":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}